12 February 2026
EMA/CHMP/38464/2025
EMEA/H/C/004917

Public statement

Palforzia (defatted powder of *Arachis hypogaea L.*, semen (peanuts))

Cessation of marketing in the European Union

On 4 December 2025, the European Medicines Agency was notified by the marketing authorisation holder of Palforzia, Stallergenes, of its decision to stop marketing the product in the European Union (EU) by 31 March 2027. This applies to all presentations except the initial dose escalation presentation (13 capsules (2 x 0.5 mg + 11 x 1 mg)), for which marketing will stop on 31 March 2026.

This decision was based on commercial reasons.

Palforzia was granted marketing authorisation in the EU on 17 December 2020 for desensitisation of children and adolescents to peanut allergy. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity on 5 December 2025.

No new patients should be started on Palforzia after 31 March 2026. There are no authorised therapeutic alternatives available in the EU. Patients taking Palforzia or participating in a clinical trial are advised to consult their physician.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union